Cancer stem cell as a potential therapeutic target in hepatocellular carcinoma

Current Cancer Drug Targets

Volumn 12, Issue 9, 2012, Pages 1081-1094

  Pang, Roberta W C ^a   Poon, Ronnie T P ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cancer stem cells; Hepatocellular carcinoma; Molecular signaling pathways; Targeted therapy

Indexed keywords

ABC TRANSPORTER; BETA CATENIN; BMI1 PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CELL SURFACE MARKER; EPITHELIAL CELL ADHESION MOLECULE; HEPATOCYTE NUCLEAR FACTOR; HERMES ANTIGEN; INTERLEUKIN 6; MICRORNA; MICROSOMAL AMINOPEPTIDASE; MULTIDRUG RESISTANCE PROTEIN; NOTCH RECEPTOR; REACTIVE OXYGEN METABOLITE; SONIC HEDGEHOG PROTEIN; T CELL FACTOR PROTEIN; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER REGENERATION; METASTASIS; MICROARRAY ANALYSIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; UPREGULATION; WNT SIGNALING PATHWAY;

EID: 84872572939     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912803987995     Document Type: Article

References (175)

1. Bosch, F. X.; Ribes, J.; Cleries, R.; Diaz, M. Epidemiology of hepatocellular carcinoma. Clin. Liver Dis. 2005, 9, 191-211.
2. Poon, R. T.; Fan, S. T.; Lo, C. M.; Ng, I. O.; Liu, C. L.; Lam, C. M.; Wong, J. Improving survival results after resection of hepatocellular carcinoma. A prospective study of 377 patients over 10 years. Ann. Surg. 2001, 234, 63-70.
3. Mazzaferro, V.; Regalia, E.; Doci, R.; Andreola, S.; Pulvirenti, A.; Bozzetti, F.; Montalto, F.; Ammatuna, M.; Morabito, A.; Gennari, L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996, 334, 693-699.
4. Poon, R. T.; Ng, K. K.; Lam, C. M.; Ai, V.; Yuen, J.; Fan, S. T. Effectiveness of radiofrequency ablation for hepatocellular carcinomas larger than 3 cm in diameter. Arch. Surg. 2004, 139, 281-287.
5. Poon, R. T.; Fan, S. T.; Wong, J. Risk factors, prevention and management of recurrence after resection of hepatocellular carcinoma. Ann. Surg. 2000, 232, 10-24.
6. Schwartz, M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2004, 127, 268-276.
7. Ng, K. K.; Poon, R. T.; Lo, C. M.; Yuen, J.; Tso, W. K.; Fan, S. T. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J. Gastrointest. Surg. 2008, 12, 183-191.
8. Llovet, J. M.; Bruix, J. Systemic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37, 429-432.
9. Lopez, P. M.; Villanueva, A.; Llovet, J. M. Systemic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. Aliment. Pharmacol. Ther. 2006, 23, 1535-1547.
10. Yeo, W.; Mok, T. S.; Zee, B.; Leung, T. W.; Lai, P. B.; Lau, W. Y.; Koh, J.; Mo, F. K.; Yu, S. C.; Chan, A. T.; Hui, P.; Ma, B.; Lam, K. C.; Ho, W. M.; Wong, H. T.; Tang, A.; Johnson, P. J. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl. Cancer Inst. 2005, 97, 1532-1538.
11. Lau, C. K.; Yang, Z. F.; Ho, D. W.; Ng, M. N.; Yeoh, G. C.; Poon, R. T.; Fan, S. T. An Akt/hypoxia-inducible factor-1alpha/plateletderived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin. Cancer Res. 2009, 15, 3462-3471.
12. Noda, T.; Nagano, H.; Takemasa, I.; Yoshioka, S.; Murakami, M.; Wada, H.; Kobayashi, S.; Marubashi. S.; Takeda, Y.; Dono, K.; Umeshita, K.; Matsuura, N.; Matsubara, K.; Doki, Y.; Mori, M.; Monden, M. Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br. J. Cancer 2009, 100, 1647-1658.
13. Llovet, J. M.; Ricci, S.; Mazaferro, V.; Hilgard, P.; Gane, E.; Blanc, J. F.; de Oliveira, A. C.; Santoro, A.; Raoul, J. L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T. F.; Galle, P. R.; Seitz, J. F.; Borbath, I.; Häussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359, 378-390.
14. Cheng, A. L.; Kang, Y. K.; Chen, Z.; Tsao, C. J.; Qin, S.; Kim, J. S.; Luo, R.; Feng, J.; Ye, S.; Yang, T.S.; Xu, J.; Sun, Y.; Liang, H.; Liu, J.; Wang, J.; Tak, W.Y.; Pan, H.; Burock, K.; Zou, J.; Voliotis, D.; Guan, Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10, 25-34.
15. Yau, T.; Chan, P.; Ng, K. K.; Chok, S. H.; Cheung, T. T.; Fan, S. T.; Poon, R. T. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis Bendemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009, 115, 428-436.
16. Yau, T.; Pang, R.; Chan, P.; Poon, R. T. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib. Expert Opin. Pharmacother. 2010, 11, 2187-2198.
17. Klonisch, T.; Wiechec, E.; Hombach-Klonisch, S.; Ande, S. R.; Wesselborg, S.; Schulze-Osthoff, K.; Los, M. Cancer stem cell markers in common cancers-therapeutic implications. Trends Mol. Med. 2008, 14, 450-460.
18. Wang, J. C.; Dick, J. E. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 2005, 15, 494-501.
19. Al-Hajj, M.; Wicha, M. S.; Benito-Hernandez, A.; Morrison, S. J.; Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 3983-3988.
20. O'Brien, C. A.; Pollett, A.; Gallinger, S.; Dick, J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445, 106-110.
21. Singh, S. K.; Hawkins, C.; Clarke, I. D.; Squire, J. A.; Bayani, J.; Hide, T.; Henkelman, R. M.; Cusimano, M. D.; Dirks, P. B. Identification of human brain tumor initiating cells. Nature 2004, 432, 396-401.
22. Collin, A. T.; Berry, P. A.; Hyde, C.; Stower, M. J.; Maitland, N. J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65, 10946-10951.
23. Pang, R.; Law, W. L.; Chu, A. C.; Poon, J. T.; Lam, C. S.; Chow, A. K.; Ng, L.; Cheung, L. W.; Lan, X. R.; Lan, H. Y.; Tan, V. P.; Yau, T. C.; Poon, R. T.; Wong, B. C. Cell Stem Cell 2010, 6, 603-615.
24. Alison, M. R. Liver stem cells: implications for hepatocarcinogenesis. Stem Cell Rev. 2005, 1, 253-260.
25. Overturf, K.; Al-Dhalimy, M.; Ou, C.N.; Finegold, M.; Grompe, M. Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse hepatocytes. Am. J. Pathol. 1997, 151, 1273-1280.
26. Bralet, M. P.; Pichar, V.; Ferry, N. Demonstration of direct lineage between hepatocytes and hepatocytes and hepatocellular carcinoma in diethylnitro-samine treated rats. Hepatology 2002, 36, 623-630.
27. Williams, G. M.; Gebhardt, R.; Sirma, H.; Stenback, F. Nonlinearity of neoplastic conversion induced in rat liver by low exposures to diethylnitrosamine. Carcinogenesis 1993, 14, 2149-2156.
28. Libbrecht. L.; De Vos, R.; Cassiman, D.; Desmet, V.; Aerts, R.; Roskams, T. Hepatic progenitor cells in hepatocellular adenoma. Am. J. Surg. Pathol. 2001, 25, 1388-1396.
29. Farber, E. Similarities in the sequence of early histologic changes induced in the liver by ethionine,2-acetylaminofluorene, and 3-methyl-4-dimethylamionazobenzene. Cancer Res. 1956, 16, 142-148.
30. Alison, M. R.; Golding, M.; Sarraf, C. E.; Edwards, R. J.; Lalani, E. N. Liver damage in the rat induces hepatocyte stem cells from biliary epithelial cells. Gastroenterology 1996, 110, 1182-1190.
31. Libbrecht, L.; Desmet, V.; Roskams, T. Preneoplastic lesions in human hepatocarcinogenesis. Liver Int. 2005, 25, 16-27.
32. Lowes, K. N.; Brennan, B. A.; Yeoh, G. C.; Olynyk, J. K. Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am. J. Pathol. 1999, 154, 537-441.
33. Dumble, M. L.; Croager, E. J.; Yeoh, G. C.; Quail, E. A. Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma. Carcinogenesis 2002, 23, 435-445.
34. Petersen, B. E.; Bowen, W. C.; Patrene, H. K.; Mars, W. M.; Sullivan, A. K.; Murase, N.; Boggs, S. S.; Greenberger, J. S.; Goff, J. P. Bone marrow as a potential source of hepatic oval cells. Science 1999, 284, 1168-1170.
35. Oh, S. H.; Witek, R. P.; Bae, S. H.; Zheng, D.; Jung, Y.; Piscaglia, A. C.; Peterson, B. E. Bone marrow-derived hepatic oval cells differentiate into hepatocytes in 2-acetylaminofluorene/partial hepatectomy-induced liver regeneration. Gastroenterology 2007, 132, 1077-1087.
36. Thorgeirsson, S. S.; Grisham, J. W. Hematopoietic cells as hepatocyte stem cells: a critical review of the evidence. Hepatology 2006, 43, 2-8.
37. Wu, X. Z.; Chen, D. Origin of hepatocellular carcinoma: role of stem cells. J. Gastroenterol. Hepatol. 2006, 21, 1093-1098.
38. Ishikawa, H.; Nakao, K.; Matsumoto, K.; Nishimura, D.; Ichikawa, T.; Hamasaki. K.; Eguchi, K. Bone marrow engraftment in a rodent model of chemical carcinogenesis but no role in the histogenesis of hepatocellular carcinoma. Gut. 2004, 53, 884-889.
39. Zheng, J. F.; Liang, L. J. Transplanted bone marrow stromal cells are not cellular origin of hepatocellular carcinomas in a mouse model of carcinogenesis. World J. Gastroenterol. 2008, 14, 3015-3020.
40. Hirschmann-Jax, C.; Foster, A. E.; Wulf, G. G.; Nuchtern, J. G.; Jax, T. W.; Gobel, U.; Goodell, M.A.; Brenner, M.K. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA 2004, 101, 14228-14233.
41. Chiba, T.; Kita, K.; Zheng, Y. W.; Yokosuka, O.; Saisho, H.; Iwama, A.; Nakauchi, H.; Taniguchi, H. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties, Hepatology 2006, 44, 240-251.
42. Shi, G. M.; Xu, Y.; Fan, J.; Zhou, J.; Yang, X. R.; Qiu, S. J.; Liao, Y.; Wu, W. Z.; Ji, Y.; Ke, A. W.; Ding, Z. B.; He, Y. Z.; Wu, B.; Yang, G. H.; Qin, W. Z.; Zhang, W.; Zhu, J.; Min, Z. H.; Wu, Z. Q. Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J. Cancer Res. Clin. Oncol. 2008, 134, 1155-1163.
43. Kondo, T.; Setoguchi, T.; Taga, T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc. Natl. Acad. Sci. USA 2004, 101, 781-786.
44. Hill, R. P. Identifying cancer stem cells in solid tumors: Case not proven. Cancer Res. 2006, 66, 1891-1895.
45. Lichtenauer, U. D.; Shapiro, I.; Geiger, K.; Quinkler, M.; Fassnacht, M.; Nitschke, R.; Rückauer, K. D.; Beuschlein, F. Side population does not define stem cell-like cancer cells in the adrenocortical carcinoma cell line NCI h295R. Endocrinology 2008, 149, 1314-1322.
46. Ricci-vitiani, L.; Lombardi, D. G.; Pilozzi, E.; Biffoni, M.; Todaro, M.; Peschle, C.; De Maria, R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445, 111-115.
47. Bertolini, G.; Roz, L.; Perego, P.; Tortoreto, M.; Fontanella, E.; Gatti, L.; Pratesi, G.; Fabbri, A.; Andriani, F.; Tinelli, S.; Roz, E.; Caserini, R.; Lo Vullo, S.; Camerini, T.; Mariani, L.; Delia, D.; Calabrò, E.; Pastorino, U.; Sozzi, G. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. USA 2009, 106, 16281-16286.
48. Roundtree, C. B.; Barsky, L.; Ge, S.; Zhu, J.; Senadheera, S.; Crooks, G. M. A CD133expressing murine liver oval cell population with bi-lineage potential. Stem Cells 2007, 25, 2419-2429.
49. Rountree, C. B.; Senadheera, S.; Mato, J. M.; Crooks, G. M.; Lu, S. C. Expansion of liver cancer stem cells during aging in methionine adenosyltransferase 1A-deficient mice. Hepatology 2008, 47, 1288-1297.
50. Rountree, C. B.; Ding, W.; He, L.; Stiles, B. Expansion of CD133 expressing liver cancer stem cells in liver specific PTEN deleted mice. Stem Cells 2009, 27, 290-299.
51. Yin, S.; Li, J.; Hu, C.; Chen, X.; Yao, M.; Yan, M.; Jiang, G.; Ge, C.; Xie, H.; Wan, D.; Yang, S.; Zheng, S.; Gu, J. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity, Int. J. Cancer 2007, 120, 1444-1450.
52. Ma, S.; Chan, K. W.; Hu, L.; Lee, T. K.; Wo, J. Y.; Ng, I. O.; Zheng, B. J.; Guan, X. Y. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007, 132, 2542-2556.
53. Song, W.; Li, H.; Tao, K.; Li, R.; Song, Z.; Zhao, Q.; Zhang, F.; Dou, K. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int. J. Clin. Pract. 2008, 62, 1212-1218.
54. Sasaki, A.; Kamiyama, T.; Yokoo, H.; Nakanishi, K,.; Kubota, K.; Haga, H.; Matsushita, M.; Ozaki, M.; Matsuno. Y.; Todo, S. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol. Rep. 2010, 24, 537-546.
55. Hou, Y.; Zou, Q.; Ge, R.; Shen, F.; Wang, Y. The critical role of CD133(+)CD44(+/high) tumor cells in hematogenous metastasis of liver cancers. Cell Res. 2012, 22, 259-272.
56. Salnikov, A. V.; Kusumawidjaja, G.; Rausch, V.; Bruns, H.; Gross, W.; Khamidjanov, A.; Ryschich, E.; Gebhard, M. M.; Moldenhauer, G.; Büchler, M. W.; Schemmer, P.; Herr, I. Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett. 2008, 275, 185-193.
57. Dalerba, P., Dylla, S. J.; Park, I. K.; Liu, R.; Wang, X.; Cho, R. W.; Hoey, T.; Gurney, A.; Huang, E. H.; Simeone, D. M.; Shelton, A. A.; Parmiani, G.; Castelli, C.; Clarke, M. F. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 2007, 104, 10158-10163.
58. Zhu, Z.; Hao, X.; Yan, M.; Yao, M.; Ge, C.; Gu, J.; Li, J. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int. J. Cancer 2010, 126, 2067-2078.
59. Ma, S.; Chan, K. W.; Lee, T. K.; Tang, K. H.; Wo, J. Y.; Zheng, B. J.; Guan, X. Y. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol. Cancer Res. 2008, 6, 1146-1153.
60. Yang, W.; Yan, H. X.; Chen, L.; Liu, Q.; He, Y. Q.; Yu, L. X.; Zhang, S. H.; Huang, D. D.; Tang, L.; Kong, X. N.; Chen, C.; Liu, S. Q.; Wu, M. C.; Wang, H. Y. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res. 2008, 68, 4287-4295.
61. Schmelzer, E.; Wauthier, E.; Reid, L. M. The phenotypes of pluripotent human hepatic progenitors. Stem Cells 2006, 24, 1852-1858.
62. Yamashita, T.; Budhu, A.; Forgues, M.; Wang, X. W. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res. 2007, 67, 10831-10839.
63. Yamashita, T.; Ji, J.; Budhu, A.; Forgues, M.; Yang, W.; Wang, H. Y.; Jia, H.; Ye, Q.; Qin, L. X.; Wauthier, E.; Reid, L. M.; Minato, H.; Honda, M.; Kaneko, S.; Tang, Z. Y.; Wang, X. W. EpCAMpositive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features, Gastroenterology 2009, 36, 1012-1024.
64. Kimura, O.; Takahashi, T.; Ishii, N.; Inoue, Y.; Ueno, Y.; Kogure, T.; Fukushima, K.; Shiina, M.; Yamagiwa, Y.; Kondo, Y.; Inoue, J.; Kakazu, E.; Iwasaki, T.; Kawagishi, N.; Shimosegawa, T.; Sugamura, K. Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines. Cancer Sci. 2010, 101, 2145-2155.
65. Yang, Z. F.; Ho, D. W.; Ng, M. N.; Lau, C. K.; Yu, W. C.; Ngai, P.; Chu, P. W.; Lam, C. T.; Poon, R. T.; Fan, S. T. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008, 13, 153-166.
66. Herrera, M. B.; Bruno, S.; Buttiglieri, S.; Tetta, C.; Gatti, S.; Deregibus, M. C.; Bussolati, B.; Camussi, G. Isolation and characterization of a stem cell population from adult human liver. Stem Cells 2006, 24, 2840-2850.
67. Dan, Y. Y.; Riehle, K. J.; Lazaro, C.; Teoh, N.; Haque, J.; Campbell, J. S.; Fausto, N. Isolation of multipotent progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal lineages. Proc. Natl. Acad. Sci. USA 2006, 103, 9912-9917.
68. Lara-Pezzi, E.; Serrador, J. M.; Montoya, M. C.; Zamora, D.; Yanez-Mo, M.; Carretero, M.; Furthmayr, H.; Sánchez-Madrid, F.; López-Cabrera, M. The hepatitis B virus X protein (HBx) induces a migratory phenotype in a CD44-dependent manner: possible role of HBx in invasion and metastasis. Hepatology 2001, 33, 1270-1281.
69. Yang, Z. F.; Ngai, P.; Ho, D. W.; Yu, W. C.; Ng, M. N.; Lau, C. K.; Li, M. L.; Tam, K. H; Lam, C. T.; Poon, R. T.; Fan, S. T. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 2008, 47, 919-928.
70. Lu, J. W.; Chang, J. G.; Yeh, K. T.; Chen, R. M.; Tsai, J. J.; Hu, R. M. Overexpression of Thy1/CD90 in human hepatocellular carcinoma is associated with HBV infection and poor prognosis. Acta. Histochem. 2011, 113, 833-838.
71. Haraguchi, N.; Ishii, H.; Mimori, K.; Tanaka, F.; Ohkuma, M.; Kim, H. M.; Akita, H.; Takiuchi, D.; Hatano, H.; Nagano, H.; Barnard, G. F.; Doki, Y.; Mori, M. CD13 is a therapeutic target in human liver cancer stem cells. J. Clin. Invest. 2010, 120, 3326-3339.
72. Gutova, M.; Najbauer. J.; Gevorgyan, A.; Metz, M. Z.; Weng, Y.; Shih, C. C.; Aboody, K. S. Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS ONE 2007, 2, e243.
73. Liu, G.; Yuan, X.; Zeng, Z.; Tunici, P.; Ng, H.; Abdulkadir, I. R.; Lu, L.; Irvin, D.; Black, K. L.; Yu, J. S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 2006, 5, 67.
74. Bao, S.; Wu, Q.; McLendon, R. E.; Hao, Y.; Shi, Q.; Hjelmeland, A. B.; Dewhirst, M. W.; Bigner, D. D.; Rich, J. N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444, 756-760.
75. Li, X. X.; Wang, J.; Wang, H. L.; Wang, W.; Yin, X. B.; Li, Q. W.; Chen, Y. Y.; Yi, J. Characterization of cancer stem-like cells derived from a side population of a human gallbladder carcinoma cell line, SGC-996. Biochem. Biophys. Res. Commun. 2012, 419, 728-734.
76. Koukourakis, M. I.; Giatromanolaki, A.; Tsakmaki, V.; Danielidis, V.; Sivridis, E. Cancer stem cell phenotype relates to radiochemotherapy outcome in locally advanced squamous cell headneck cancer. Br. J. Cancer 2012, 106, 846-853.
77. Steg, A. D.; Bevis, K. S.; Katre, A. A.; Ziebarth, A.; Dobbin, Z. C.; Alvarez, R. D.; Zhang, K.; Conner, M.; Landen, C. N. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin. Cancer Res. 2012, 18, 869-881.
78. Piao, L. S.; Hur, W.; Kim, T. K.; Hong, S. W.; Kim, S. W.; Choi, J. E.; Sung, P. S.; Song, M. J.; Lee, B. C.; Hwang, D.; Yoon, S. K. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett. 2012, 315, 129-137.
79. Ros, J. E.; Libbrecht, L.; Geuken, M.; Jansen, P. L.; Roskams, T. A. High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. J. Pathol. 2003, 200, 553-560.
80. Vander Borght, S.; Libbrecht, L.; Katoonizadeh, A.; van Pelt, J.; Cassiman, D.; Nevens, F.; Van Lommel, A.; Petersen, B. E.; Fevery, J.; Jansen, P. L.; Roskams, T. A. Breast cancer resistance protein (BCRP/ABCG2) is expressed by progenitor cells/reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: possible functional consequences. J. Histochem. Cytochem. 2006, 54, 1051-1059
81. Kato, A.; Miyazaki, M.; Ambiru, S.; Yoshitomi, H.; Ito, H.; Nakagawa, K.; Shimizu, H.; Yokosuka, O.; Nakajima, N. Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J. Surg. Oncol. 2001, 78, 110-115.
82. Ng, I. O.; Liu, C. L.; Fan, S. T.; Ng, M. Expression of Pglycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am. J. Clin. Pathol. 2000, 113, 355-363.
83. Vander Borght, S.; Komuta, M.; Libbrecht, L.; Katoonizadeh, A.; Aerts, R.; Dymarkowski, S.; Verslype, C.; Nevens, F.; Roskams, T. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int. 2008, 28, 1370-1380.
84. Doyle, L. A.; Ross, D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003, 22, 7340-7358.
85. Zhou, S.; Schuetz, J. D.; Bunting, K. D.; Colapietro, A. M.; Sampath, J.; Morris, J. J.; Lagutina, I.; Grosveld, G. C.; Osawa, M.; Nakauchi, H.; Sorrentino, B. P. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 2001, 7, 1028-1034.
86. Shimano, K.; Satake, M.; Okaya, A.; Kitanaka, J.; Kitanaka, N.; Takemura, M.; Sakagami, M.; Terada, N.; Tsujimura, T. Hepatic oval cells have the side population phenotype defined by expression of ATP-binding cassette transporter ABCG2/BCRP1. Am. J. Pathol. 2003, 163, 3-9.
87. Zen, Y.; Fujii, T.; Yoshikawa, S.; Takamura, H.; Tani, T.; Ohta, T.; Nakanuma, Y. Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma. Am. J. Pathol. 2007, 170, 1750-1762.
88. Hu, C.; Li, H.; Li, J.; Zhu, Z.; Yin, S.; Hao, X.; Yao, M.; Zheng, S.; Gu, J. Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis 2008, 29, 2289-2297.
89. Ma, S.; Lee, T. K.; Zheng, B. J.; Chan, K. W.; Guan, X. Y. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008, 27, 1749-1758.
90. Wang, X. Q.; Ongkeko, W. M.; Chen, L.; Yang, Z. F.; Lu, P.; Chen, K. K.; Lopez, J. P.; Poon, R. T.; Fan, S. T. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology 2010, 52, 528-539.
91. Yilmaz, O. H.; Valdez, R.; Theisen, B. K.; Guo, W.; Ferguson, D. O.; Wu, H.; Morrison, S. J. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006, 441, 475-482.
92. Reya, T.; Clevers, H. Wnt signalling in stem cells and cancer. Nature 2005, 434, 843-850.
93. Clevers, H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127, 469-480.
94. Hsu, H. C.; Jeng, Y. M.; Mao, T. L.; Chu, J. S.; Lai, P. L.; Peng, S. Y. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am. J. Pathol. 2005, 157, 763-770.
95. Wong, C. M.; Fan, S. T.; Ng, I. O. beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 2001, 92, 136-145.
96. de La Coste, A.; Romagnolo, B.; Billuart P.; Renard, C. A.; Buendia, M. A.; Soubrane, O.; Fabre, M.; Chelly, J.; Beldjord, C.; Kahn, A.; Perret, C. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad. Sci. USA 1998, 95, 8847-8851.
97. Takigawa, Y.; Brown, A. M. Wnt signaling in liver cancer. Curr. Drug Targets 2008, 9, 1013-1024.
98. Taniguchi, K.; Roberts, L. R.; Aderca, I. N.; Dong, X.; Qian, C.; Murphy, L. M.; Nagorney, D. M.; Burgart, L. J.; Roche, P. C.; Smith, D. I.; Ross, J. A.; Liu, W. Mutational spectrum of betacatenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002, 21, 4863-4871.
99. Zucman-Rossi, J.; Benhamouche, S.; Godard, C.; Boyault, S.; Grimber, G.; Balabaud, C.; Cunha, A. S.; Bioulac-Sage, P.; Perret, C. Differential effects of inactivated Axin1 and activated betacatenin mutations in human hepatocellular carcinomas. Oncogene 2007, 26, 774-780.
100. Merle, P.; de la Monte, S.; Kim, M.; Herrmann, M.; Tanaka, S.; Von Dem Bussche, A.; Kew, M. C.; Trepo, C.; Wands, J. R. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 2004, 127, 1110-1122.
101. Bengochea, A.; de Souza, M. M.; Lefrancois, L.; Le Roux, E.; Galy, O.; Chemin, I.; Kim, M.; Wands, J. R.; Trepo, C.; Hainaut, P.; Scoazec, J. Y.; Vitvitski, L.; Merle, P. Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br. J. Cancer 2008, 99, 143-150.
102. Pang, R.; Yuen, J.; Yuen, M. F.; Lai, C. L.; Lee, T. K.; Man, K.; Poon, R. T.; Fan, S. T.; Wong, C. M.; Ng, I. O.; Kwong, Y. L.; Tse, E. PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene 2004, 23, 4182-4186.
103. Malanchi, I.; Peinado, H.; Kassen, D.; Hussenet, T.; Metzger, D.; Chambon, P.; Huber, M.; Hohl, D.; Cano, A.; Birchmeier, W.; Huelsken, J. Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 2008, 452, 650-653.
104. Lee, J. S.; Heo, J.; Libbrecht, L.; Chu, I. S.; Kaposi-Novak, P.; Calvisi, D. F.; Mikaelyan, A.; Roberts, L. R.; Demetris, A. J.; Sun, Z.; Nevens, F.; Roskams, T.; Thorgeirsson, S. S. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med. 2006, 12, 410-416.
105. Yuan, F.; Zhou, W.; Zou, C.; Zhang, Z.; Hu, H.; Dai, Z.; Zhang, Y. Expression of Oct4 in HCC and modulation to Wnt/β-catenin and TGF-β signal pathways. Mol. Cell. Biochem. 2010, 343, 155-162.
106. Artavanis-Tsakonas, S.; Rand, M. D.; Lake, R. J. Notch signaling: cell fate control and signal integration in development. Science 1999, 284, 770-776.
107. Gordon, W. R.; Vardar-Ulu, D.; Histen, G.; Sanchez-Irizarry, C.; Aster, J. C.; Blacklow, S. C. Structural basis for autoinhibition of Notch. Nat. Struct. Mol. Biol. 2007, 14, 295-300.
108. Tien, A. C.; Rajan, A.; Bellen, H. J. A Notch updated. J. Cell Biol. 2009, 184, 621-619.
109. Hu, Y. Y.; Zheng, M. H.; Cheng, G.; Li, L.; Liang, L.; Gao, F.; Wei, Y. N.; Fu, L. A.; Han, H. Notch signaling contributes to the maintenance of both normal neural stem cells and patient-derived glioma stem cells. BMC Cancer 2011, 11, 82.
110. Grudzien, P.; Lo, S.; Albain, K. S.; Robinson, P.; Rajan, P.; Strack, P. R.; Golde, T. E.; Miele, L.; Foreman, K. E. Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Res. 2010, 30, 3853-3867.
111. Sikandar, S. S.; Pate, K. T.; Anderson, S.; Dizon, D.; Edwards, R. A.; Waterman, M. L.; Lipkin, S. M. NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res. 2010, 70, 1469-1478.
112. Giovannini, C.; Lacchini, M.; Gramantieri, L.; Chieco, P.; Bolondi, L. Notch3 intracellular domain accumulates in HepG2 cell line. Anticancer Res. 2006; 26, 2123-2127.
113. Gramantieri, L.; Giovannini, C.; Lanzi, A.; Chieco, P.; Ravaioli, M.; Venturi, A.; Grazi, G. L.; Bolondi, L. Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. Liver Int. 2007, 27, 997-1007.
114. Gao, J.; Chen, C.; Hong, L.; Wang, J.; Du, Y.; Song, J.; Shao, X.; Zhang, J.; Han, H.; Liu, J.; Fan, D. Expression of Jagged1 and its association with hepatitis B virus X protein in hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2007, 356, 341-347.
115. Gao, J.; Song, Z.; Chen, Y.; Xia, L.; Wang, J.; Fan, R.; Du, R.; Zhang, F.; Hong, L.; Song, J.; Zou, X.; Xu, H.; Zheng, G.; Liu, J.; Fan, D. Deregulated expression of Notch receptors in human hepatocellular carcinoma. Dig. Liver Dis. 2008, 40, 114-121.
116. Ingham, P. W.; McMahon, A. P. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 2001, 15, 3059-3087.
117. Yauch, R. L.; Gould, S. E.; Scales, S. J.; Tang, T.; Tian, H.; Ahn, C. P.; Marshall, D.; Fu, L.; Januario, T.; Kallop, D.; Nannini-Pepe, M.; Kotkow, K.; Marsters, J. C.; Rubin, L. L.; de Sauvage, F. J. A paracrine requirement for hedgehog signalling in cancer. Nature 2008, 455, 406-410.
118. Hahn, H.; Wicking, C.; Zaphiropoulous, P. G.; Gailani, M. R.; Shanley, S.; Chidambaram, A.; Vorechovsky, I.; Holmberg, E.; Unden, A. B.; Gillies, S.; Negus, K.; Smyth, I.; Pressman, C.; Leffell, D. J.; Gerrard, B.; Goldstein, A. M.; Dean, M.; Toftgard, R.; Chenevix-Trench, G.; Wainwright, B.; Bale, A. E. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996, 85, 841-851.
119. Zhao, C.; Chen, A.; Jamieson, C. H.; Fereshteh, M.; Abrahamsson, A.; Blum, J.; Kwon, H. Y.; Kim, J.; Chute, J. P.; Rizzieri, D.; Munchhof, M.; VanArsdale, T.; Beachy, P. A.; Reya, T. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458, 776-779.
120. Song, Z.; Yue, W.; Wei, B.; Wang, N.; Li, T.; Guan, L.; Shi, S.; Zeng, Q.; Pei, X.; Chen, L. Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PLoS One 2011, 6, e17687.
121. Varnat, F.; Duquet, A.; Malerba, M.; Zbinden, M.; Mas, C.; Gervaz, P.; Ruiz, I.; Altaba, A. Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol. Med. 2009, 1, 338-351.
122. Tanaka, H.; Nakamura, M.; Kameda, C.; Kubo, M.; Sato, N.; Kuroki, S.; Tanaka, M.; Katano, M. The Hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24-/low subpopulation and the side population of breast cancer cells. Anticancer Res. 2009, 29, 2147-2157.
123. Dembinski, J. L.; Krauss, S. Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin. Exp. Metastasis 2009, 26, 611-623.
124. Huang, S.; He, J.; Zhang, X.; Bian, Y.; Yang, L.; Xie, G.; Zhang, K.; Tang, W.; Stelter, A. A.; Wang, Q.; Zhang, H.; Xie. J. Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis 2006, 27, 1334-1340.
125. Cheng, W. T.; Xu, K.; Tian, D. Y.; Zhang, Z. G.; Liu, L. J.; Chen, Y. Role of Hedgehog signaling pathway in proliferation and invasiveness of hepatocellular carcinoma cells. Int. J. Oncol. 2009, 34, 829-836.
126. Chen, X.; Lingala, S.; Khoobyari, S.; Nolta, J.; Zern, M. A.; Wu, J. Epithelial mesenchymal transition and Hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J. Hepatol. 2011, 55, 838-845.
127. Mishra, L.; Derynck, R.; Mishra, B. Transforming growth factorbeta signaling in stem cells and cancer. Science 2005, 310, 68-71.
128. Mishra, L.; Shetty, K.; Tang, Y.; Stuart, A.; Byers, S. W. The role of TGFbeta and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene 2005, 24, 5775-5789.
129. Tang, Y.; Kitisin, K.; Jogunoori, W.; Li, C.; Deng, C. X.; Mueller, S. C.; Ressom, H. W.; Rashid, A.; He, A. R.; Mendelson, J. S.; Jessup, J. M.; Shetty, K.; Zasloff, M.; Mishra, B.; Reddy, E. P.; Johnson, L.; Mishra, L. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc. Natl. Acad. Sci. USA 2008, 105, 2445-2450.
130. You, H.; Ding, W.; Rountree, C. B. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 2010, 51, 1635-1644.
131. Chiba, T.; Seki, A.; Aoki, R.; Ichikawa, H.; Negishi, M.; Miyagi, S.; Oguro, H.; Saraya, A.; Kamiya, A.; Nakauchi, H.; Yokosuka, O.; Iwama, A. Bmi1 promotes hepatic stem cell expansion and tumorigenicity in both Ink4a/Arf-dependent and-independent manners in mice. Hepatology 2010, 52, 1111-1123.
132. Chiba, T.; Miyagi, S.; Saraya, A.; Aoki, R.; Seki, A.; Morita, Y.; Yonemitsu, Y.; Yokosuka, O.; Taniguchi, H.; Nakauchi, H.; Iwama, A. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res. 2008, 68, 7742-7749.
133. Sasaki, M.; Ikeda, H.; Itatsu, K.; Yamaguchi, J.; Sawada, S.; Minato, H.; Ohta, T.; Nakanuma, Y. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab. Invest. 2008, 88, 873-882.
134. Effendi, K.; Mori, T.; Komuta, M.; Masugi, Y.; Du, W.; Sakamoto, M. Bmi-1 gene is upregulated in early-stage hepatocellular carcinoma and correlates with ATP-binding cassette transporter B1 expression. Cancer Sci. 2010, 101, 666-672.
135. Cheung, R. S.; Brooling, J. T.; Johnson, M. M.; Riehle, K. J.; Campbell, J. S.; Fausto, N. Interactions between MYC and transforming growth factor alpha alter the growth and tumorigenicity of liver progenitor cells. Carcinogenesis 2007, 28, 2624-2631.
136. Jin, C.; Samuelson, L.; Cui, C. B.; Sun, Y.; Gerber, D. A. MAPK/ERK and Wnt/β-Catenin pathways are synergistically involved in proliferation of Sca-1 positive hepatic progenitor cells. Biochem. Biophys. Res. Commun. 2011, 409, 803-807.
137. Yeoh, G. C.; Ernst, M.; Rose-John, S.; Akhurst, B.; Payne, C.; Long, S.; Alexander, W.; Croker, B.; Grail, D; Matthews, V. B. Opposing roles of gp130-mediated STAT-3 and ERK-1/ 2 signaling in liver progenitor cell migration and proliferation. Hepatology 2007, 45, 486-494.
138. Mallanna, S. K.; Rizzino, A. Emerging roles of microRNAs in the control of embryonic stem cells and the generation of induced pluripotent stem cells. Dev. Biol. 2010, 344, 16-25.
139. DeSano, J. T.; Xu, L. MicroRNA regulation of cancer stem cells and therapeutic implications. AAPS J. 2009, 11, 682-692.
140. Wong, P.; Iwasaki, M.; Somervaille, T. C.; Ficara, F.; Carico, C.; Arnold, C.; Chen, C. Z.; Cleary, M. L. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res. 2010, 70, 3833-3842.
141. Lo, W. L.; Yu, C. C.; Chiou, G. Y.; Chen, Y. W.; Huang, P. I.; Chien, C. S.; Tseng, L. M.; Chu, P. Y.; Lu, K. H.; Chang, K. W.; Kao, S. Y.; Chiou, S. H. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells. J. Pathol. 2011, 223, 482-495.
142. Liu, C.; Kelnar, K.; Liu, B.; Chen, X.; Calhoun-Davis, T.; Li, H.; Patrawala, L.; Yan, H.; Jeter, C.; Honorio, S.; Wiggins, J. F.; Bader, A. G.; Fagin, R.; Brown, D.; Tang, D. G. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 2011, 1, 211-215.
143. Hwang-Verslues, W. W.; Chang, P. H.; Wei, P. C.; Yang, C. Y.; Huang, C. K.; Kuo, W. H.; Shew, J. Y.; Chang, K. J.; Lee, E. Y.; Lee, W. H. miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1. Oncogene 2011, 30, 2463-2474.
144. Golestaneh, A. F.; Atashi, A.; Langroudi, L.; Shafiee, A.; Ghaemi, N.; Soleimani, M. miRNAs expressed differently in cancer stem cells and cancer cells of human gastric cancer cell line MKN-45. J. Mammary Gland Biol. Neoplasia 2012, 17, 15-21.
145. Gramantieri, L.; Fornari, F.; Callegari, E.; Sabbioni, S.; Lanza, G.; Croce, C.M.; Bolondi, L.; Negrini, M. MicroRNA involvement in hepatocellular carcinoma. J. Cell Mol. Med. 2008, 12, 2189-2204.
146. Li, R.; Qian, N.; Tao, K.; You, N.; Wang, X.; Dou, K. MicroRNAs involved in neoplastic transformation of liver cancer stem cells. J. Exp. Clin. Cancer Res. 2010, 29, 169.
147. Ji, J.; Yamashita, T.; Budhu, A.; Forgues, M.; Jia, H. L.; Li, C.; Deng, C.; Wauthier, E.; Reid, L. M.; Ye, Q. H.; Qin, L. X.; Yang, W.; Wang, H. Y.; Tang, Z. Y.; Croce, C. M.; Wang, X. W. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009, 50, 472-480.
148. Ma, S.; Tang, K. H.; Chan, Y. P.; Lee, T. K.; Kwan, P. S.; Castilho, A.; Ng, I.; Man, K.; Wong, N.; To, K. F.; Zheng, B. J.; Lai, P. B.; Lo, C. M.; Chan, K. W.; Guan, X. Y. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell. 2010, 7, 694-707.
149. Zhang, J.; Luo, N.; Luo, Y.; Peng, Z.; Zhang, T.; Li, S. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Int. J. Oncol. 2012, 40, 747-756.
150. Meng, F.; Glaser, S. S.; Francis, H.; Demorrow, S.; Han, Y.; Passarini, J. D.; Stokes, A.; Cleary, J. P.; Liu, X.; Venter, J.; Kumar, P.; Priester, S.; Hubble, L.; Stoloch, D.; Sharma, J.; Liu, C. G.; Alpini, G. Functional analysis of microRNAs in human hepatocellular cancer stem cells. J. Cell Mol. Med. 2011, 16, 160-173.
151. Stefanachi, A.; Leonetti, F.; Nicolotti, O.; Catto, M.; Pisani, L.; Cellamare, S.; Altomare C.; Carotti, A. New strategies in the chemotherapy of leukemia: Eradicating cancer stem cells in chronic myeloid leukemia. Curr. Cancer Drug Targets 2012, Mar 14. [Epub ahead of print].
152. Yau, T.; Pang, R.; Chan, P.; Poon, R. T. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib. Expert Opin. Pharmacother. 2010, 11, 2187-2198.
153. Smith, L. M.; Nesterova, A.; Ryan, M. C.; Duniho, S.; Jonas, M.; Anderson, M.; Zabinski, R. F.; Sutherland, M. K.; Gerber, H. P.; Van Orden, K. L.; Moore, P. A.; Ruben, S. M.; Carter, P.J. CD133/prominin-1 is a potential therapeutic target for antibodydrug conjugates in hepatocellular and gastric cancers. Br. J. Cancer 2008, 99, 100-109.
154. Jin, L.; Hope, K. J.; Zhai, Q.; Smadja-Joffe, J. F.;. Dick, E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 2006, 12, 1167-1174.
155. He, B.; Reguart, N.; You, L.; Mazieres, J.; Xu, Z.; Lee, A. Y.; Mikami, I.; McCormick, F.; Jablons, D. M. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 2005, 24, 3054-3058.
156. You, L.; He, B.; Xu, Z.; Uematsu, K.; Mazieres, J.; Fujii, N.; Mikami, I.; Reguart, N.; McIntosh, J. K.; Kashani-Sabet, M.; McCormick, F.; Jablons, D. M. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res. 2004, 64, 5385-5389.
157. Chen, B.; Dodge, M. E.; Tang, W.; Lu, J.; Ma, Z.; Fan, C. W.; Wei, S.; Hao, W.; Kilgore, J.; Williams, N. S.; Roth, M. G.; Amatruda, J. F.; Chen, C.; Lum, L. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 2009, 5, 100-107.
158. Hu, J.; Dong, A.; Fernandez-Ruiz, V.; Shan, J.; Kawa, M.; Martínez-Ansó, E.; Prieto, J.; Qian, C. Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma. Cancer Res. 2009, 69, 6951-6959.
159. Wei, W.; Chua, M. S.; Grepper, S.; So, S. K. Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin. Mol. Cancer 2011, 10, 16.
160. Hoey, T.; Yen, W. C.; Axelrod, F.; Basi, J.; Donigian, L.; Dylla, S.; Fitch-Bruhns, M.; Lazetic, S.; Park, I. K.; Sato, A.; Satyal, S.; Wang, X.; Clarke, M. F.; Lewicki, J.; Gurney, A. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009, 5, 168-177.
161. Peters, J. U.; Galley, G.; Jacobsen, H.; Czech, C.; David-Pierson, P.; Kitas, E. A.; Ozmen, L. Novel orally active, dibenzazepinonebased gamma-secretase inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 5918-5923.
162. Wang, Y.; Liu, Y; Malek, S. N.; Zheng, P.; Liu, Y. Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011, 8, 399-411.
163. Low, J. A.; de Sauvage, F. J. Clinical experience with Hedgehog pathway inhibitors. J. Clin. Oncol. 2010, 28, 5321-5326.
164. Lorusso, P. M.; Rudin, C. M.; Reddy, J. C.; Tibes, R.; Weiss, G. J.; Borad, M. J.; Hann, C. L.; Brahmer, J. R.; Chang, I.; Darbonne, W. C.; Graham, R. A.; Zerivitz, K. L.; Low, J.; Von Hoff, D. D. Phase I trial of hedgehog pathway inhibitor GDC-0449 in patients with refractory, locally-advanced or metastatic solid tumors. Clin. Cancer Res. 2011, 17, 2502-2511.
165. Chen, X. L.; Cheng, Q. Y.; She, M. R.; Wang, Q.; Huang, X. H.; Cao, L. Q.; Fu, X. H.; Chen, J. S. Expression of sonic hedgehog signaling components in hepatocellular carcinoma and cyclopamine-induced apoptosis through Bcl-2 downregulation in vitro. Arch. Med. Res. 2010, 41, 315-323.
166. Wang, V.; Wu, W. MicroRNA-based therapeutics for cancer. BioDrugs 2009, 23, 15-23.
167. Kota, J.; Chivukula, R. R.; O'Donnell, K. A.; Wentzel, E. A.; Montgomery, C. L.; Hwang, H. W.; Chang, T. C.; Vivekanandan, P.; Torbenson, M.; Clark, K. R.; Mendell, J. R.; Mendell, J. T. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137, 1005-1017.
168. Li, C.; Feng, Y.; Coukos, G.; Zhang, L. Therapeutic microRNA strategies in human cancer. AAPS J. 2009, 11, 747-757.
169. Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K. G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438, 685-689.
170. Piccirillo, S. G.; Reynolds, B. A.; Zanetti, N.; Lamorte, G.; Binda, E.; Broggi, G.; Brem, H.; Olivi, A.; Dimeco, F.; Vescovi, A. L. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006, 444, 761-765.
171. Parviz, F.; Matullo, C.; Garrison, W. D.; Savatski, L.; Adamson, J. W.; Ning, G. Kaestner, K. H.; Rossi, J. M.; Zaret, K. S.; Duncan, S. A. Hepatocyte nuclear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis. Nat. Genet. 2003, 34, 292-296.
172. Yin, C.; Lin, Y.; Zhang, X.; Chen, Y. X.; Zeng, X.; Yue, H. Y.; Hou, J. L.; Deng, X.; Zhang, J. P.; Han, Z. G.; Xie, W. F. Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene. Hepatology 2008, 48, 1528-1539.
173. Zhang, Y.; Song, W. J.; Zhang, F. Q.; Liu, W. H.; Dou, K. F. Differentiation-inducing activity of hydroxycamptothecin on cancer stem-like cells derived from hepatocellular carcinoma. Dig. Dis. Sci. 2011, 56, 2473-2481.
174. Livraghi, T.; Meloni, F.; Frosi, A.; Lazzaroni, S.; Bizzarri, T. M.; Frati, L.; Biava, P. M. Treatment with stem cell differentiation stage factors of intermediate-advanced hepatocellular carcinoma: an open randomized clinical trial. Oncol. Res. 2005, 15, 399-408.
175. Livraghi, T.; Ceriani, R.; Palmisano, A.; Pedicini, V.; Pich, M. G.; Tommasini, M. A.; Torzilli, G. Complete response in 5 out of 38 patients with advanced hepatocellular carcinoma treated with stem cell differentiation stage factors: Case reports from a single centre. Curr. Pharm. Biotechnol. 2011, 12, 254-260.